Thymogen: Research Overview

Thymogen is a synthetic immunomodulatory dipeptide consisting of glutamic acid and tryptophan (L-Glu-L-Trp, also written EW). It was isolated from a natural bovine thymic extract called Thymalin through reversed-phase high-performance liquid chromatography and subsequently synthesized by researchers at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. Thymogen has held regulatory approval in Russia since 1990 and is registered in three formulations: intramuscular injection, nasal spray, and topical cream. It has no FDA or EMA approval, and independent Western clinical evaluation is limited.

What is Thymogen?

Thymogen (EW dipeptide) is the smallest functional subunit identified within the Thymalin complex. Because it is a dipeptide rather than a four-amino-acid sequence, it sits alongside but slightly outside the canonical Khavinson tetrapeptide series, though it originates from the same research program and shares the same epigenetic-bioregulator framing. It is commercially supplied as a lyophilized powder for reconstitution. At the research level it is studied as a model for how minimal peptide fragments derived from thymic tissue might recapitulate broader immunomodulatory properties.

Proposed Mechanism

In cell and animal models, L-Glu-L-Trp has been reported to activate T-cell differentiation and to influence T-cell recognition of peptide-MHC complexes. The compound is also said to induce shifts in intracellular cyclic nucleotide composition and to enhance neutrophilic chemotaxis and phagocytosis. Mechanistically, the Khavinson group frames Thymogen as operating at the level of chromatin accessibility: the dipeptide is proposed to bind DNA regulatory elements and partially decondense heterochromatin, thereby increasing transcriptional availability of genes relevant to immune function. This epigenetic-level explanation remains hypothetical and is based on in vitro and rodent data from a single laboratory.

Research Summary

A 2001 study by Anisimov, Khavinson, and colleagues reported that lifetime administration of L-Glu-L-Trp to aging rats was associated with lower total and malignant tumor incidence and a slower apparent rate of aging compared with untreated controls (PMID 11707921). A separate PubMed-indexed paper documented clinical observations in which Thymogen administration was associated with normalization of T- and B-lymphocyte counts in patients with inflammatory gynecological conditions (PMID 1476231). Research involving Type 1 diabetes patients suggested immune-parameter improvements following Thymogen use (PMID 9026934). A more recent paper examined the monocyte/macrophage THP-1 cell line and found that the EW dipeptide modulated proliferative activity and inflammatory pathway markers (PMID 35408963).

Importantly, research on Thymogen is concentrated in a single Russian research group, primarily the St. Petersburg Institute of Bioregulation and Gerontology. Independent Western replication is limited, and the largest clinical reports originate from investigators with direct ties to the compound's development. No randomized controlled trials registered in ClinicalTrials.gov or the EU Clinical Trials Register are available for review. Findings from rodent longevity and tumor-suppression studies should not be extrapolated to human outcomes.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Russian clinical literature describes intramuscular doses of 50-100 mcg (0.05-0.1 mg) per day for 5-10 days as a course. Intranasal formulations delivering approximately 50 mcg per nostril per day have also been described. These figures derive from Russian-language clinical practice documentation and manufacturer labeling and have not been validated in Western dose-ranging trials.

Frequently Asked Questions

Is Thymogen the same as Thymalin?

No. Thymalin is a polypeptide complex extracted from bovine thymic tissue. Thymogen (EW dipeptide) is the isolated and synthetically reproduced active subunit identified within Thymalin. They share a biological origin but are chemically distinct preparations.

Does Thymogen have regulatory approval outside Russia?

No. Thymogen is approved in Russia as a prescription pharmaceutical. It has not received FDA, EMA, or any other Western regulatory approval. Outside Russia it is available only as an unregulated research compound.

How strong is the human evidence base for Thymogen?

Thin. Available human data consists mainly of small observational or uncontrolled clinical reports published in Russian-language or Russian-affiliated journals. No large, double-blind, placebo-controlled trials have been conducted or reported in the peer-reviewed Western literature.

References

1. Anisimov VN, Khavinson VKh, et al. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2000;1(4):369-74. PMID 11707921. https://pubmed.ncbi.nlm.nih.gov/11707921/

2. [Thymogen in the complex treatment of inflammatory diseases of the female genital system]. PMID 1476231. https://pubmed.ncbi.nlm.nih.gov/1476231/

3. [Thymogen in the treatment of type-1 diabetes mellitus]. PMID 9026934. https://pubmed.ncbi.nlm.nih.gov/9026934/

4. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. PMC. PMID 35408963. https://pubmed.ncbi.nlm.nih.gov/35408963/